{"id":45331,"date":"2025-10-30T22:20:43","date_gmt":"2025-10-30T14:20:43","guid":{"rendered":"https:\/\/flcube.com\/?p=45331"},"modified":"2025-10-30T22:20:44","modified_gmt":"2025-10-30T14:20:44","slug":"everest-medicines-secures-exclusive-rights-to-vis%e2%80%91101-in-greater-china-potential-2026-phase-3-launch","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45331","title":{"rendered":"Everest Medicines Secures Exclusive Rights to VIS\u2011101 in Greater China, Potential 2026 Phase\u202f3 Launch"},"content":{"rendered":"\n<p>Hong Kong\u2011listed Everest Medicines Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/1952:HKG\">HKG: 1952<\/a>) today announced a strategic agreement with Visara, Inc., a subsidiary of NovaBridge Biosciences (formerly I\u2011Mab, Nasdaq:\u202fNBP). Under the deal, Visara irrevocably granted Everest an exclusive license to develop, manufacture, and commercialize the bifunctional biologic <strong>VIS\u2011101<\/strong> in Greater China, Singapore, South\u202fKorea, and selected Southeast Asian markets.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-terms-and-financial-commitments\">Terms and Financial Commitments<\/h4>\n\n\n\n<p>Everest\u2019s payment structure includes an upfront fee of <strong>USD\u202f7\u202fmillion<\/strong> (\u2248\u202fRMB\u202f49.7\u202fmillion) plus a reimbursement cap of up to RMB\u202f24\u202fmillion for eligible out\u2011of\u2011pocket expenses. In addition, the company faces up to <strong>USD\u202f89\u202fmillion<\/strong> (\u2248\u202fRMB\u202f632\u202fmillion) in development and sales milestone payments, along with future net\u2011sales royalties once VIS\u2011101 reaches commercial availability.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-vis-101-a-next-generation-dual-targeted-ocular-therapeutic\">VIS\u2011101: A Next\u2011Generation, Dual\u2011Targeted Ocular Therapeutic<\/h4>\n\n\n\n<p>VIS\u2011101 is a novel bifunctional antibody that simultaneously inhibits vascular endothelial growth factor\u2011A (VEGF\u2011A) and angiopoietin\u20112 (ANG\u20112). Preclinical data suggest this dual blockade yields higher potency and potentially longer\u2011lasting benefits for patients with <strong>wet age\u2011related macular degeneration (AMD)<\/strong>, <strong>diabetic macular edema (DME)<\/strong>, and <strong>retinal vein occlusion (RVO)<\/strong> than first\u2011generation agents.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-clinical-milestones\">Clinical Milestones<\/h4>\n\n\n\n<p>The biologic has completed initial safety and dose\u2011escalation studies in both the United States and China. A randomized, dose\u2011range Phase\u202f2 trial is now concluding in the Chinese market, with the company targeting <strong>Phase\u202f3 readiness by 2026<\/strong>\u2014a critical step toward regulatory approval and market entry in the region.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h4>\n\n\n\n<p>The East Asian ophthalmology landscape represents a substantial opportunity, with projected spend on anti\u2011VEGF therapies reaching <strong>$5\u202fbillion<\/strong> over the next decade. Everest\u2019s exclusive foothold on VIS\u2011101, coupled with a robust development pipeline, positions it to capture a significant share of this high\u2011value segment, potentially reshaping the competitive hierarchy that currently favors established players such as Roche, Regeneron, and Janssen.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-investor-perspective\">Investor Perspective<\/h4>\n\n\n\n<p>Everest\u2019s agreement underscores a disciplined expansion strategy that blends scientific innovation with clear financial architecture. The upfront and milestone payments provide a predictable cash\u2011flow profile, while the royalty upside offers long\u2011term upside potential. Market watchers should monitor Phase\u202f2 outcomes, regulatory feedback, and the speed of regulatory approvals across the territories outlined in the license to gauge the eventual commercial trajectory of VIS\u2011101.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hong Kong\u2011listed Everest Medicines Limited (HKG: 1952) today announced a strategic agreement with Visara, Inc.,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45333,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[126,1164,4398,44],"class_list":["post-45331","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-everest-medicines","tag-hkg-1952","tag-novabridge-biosciences","tag-ophthalmology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Everest Medicines Secures Exclusive Rights to VIS\u2011101 in Greater China, Potential 2026 Phase\u202f3 Launch - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hong Kong\u2011listed Everest Medicines Limited (HKG: 1952) today announced a strategic agreement with Visara, Inc., a subsidiary of NovaBridge Biosciences (formerly I\u2011Mab, Nasdaq:\u202fNBP). Under the deal, Visara irrevocably granted Everest an exclusive license to develop, manufacture, and commercialize the bifunctional biologic VIS\u2011101 in Greater China, Singapore, South\u202fKorea, and selected Southeast Asian markets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45331\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest Medicines Secures Exclusive Rights to VIS\u2011101 in Greater China, Potential 2026 Phase\u202f3 Launch\" \/>\n<meta property=\"og:description\" content=\"Hong Kong\u2011listed Everest Medicines Limited (HKG: 1952) today announced a strategic agreement with Visara, Inc., a subsidiary of NovaBridge Biosciences (formerly I\u2011Mab, Nasdaq:\u202fNBP). Under the deal, Visara irrevocably granted Everest an exclusive license to develop, manufacture, and commercialize the bifunctional biologic VIS\u2011101 in Greater China, Singapore, South\u202fKorea, and selected Southeast Asian markets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45331\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-30T14:20:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-30T14:20:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3005-2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45331#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45331\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Everest Medicines Secures Exclusive Rights to VIS\u2011101 in Greater China, Potential 2026 Phase\u202f3 Launch\",\"datePublished\":\"2025-10-30T14:20:43+00:00\",\"dateModified\":\"2025-10-30T14:20:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45331\"},\"wordCount\":377,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45331#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3005-2.webp\",\"keywords\":[\"Everest Medicines\",\"HKG: 1952\",\"NovaBridge Biosciences\",\"Ophthalmology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45331#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45331\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45331\",\"name\":\"Everest Medicines Secures Exclusive Rights to VIS\u2011101 in Greater China, Potential 2026 Phase\u202f3 Launch - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45331#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45331#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3005-2.webp\",\"datePublished\":\"2025-10-30T14:20:43+00:00\",\"dateModified\":\"2025-10-30T14:20:44+00:00\",\"description\":\"Hong Kong\u2011listed Everest Medicines Limited (HKG: 1952) today announced a strategic agreement with Visara, Inc., a subsidiary of NovaBridge Biosciences (formerly I\u2011Mab, Nasdaq:\u202fNBP). Under the deal, Visara irrevocably granted Everest an exclusive license to develop, manufacture, and commercialize the bifunctional biologic VIS\u2011101 in Greater China, Singapore, South\u202fKorea, and selected Southeast Asian markets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45331#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45331\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45331#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3005-2.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3005-2.webp\",\"width\":1080,\"height\":608,\"caption\":\"Everest Medicines Secures Exclusive Rights to VIS\u2011101 in Greater China, Potential 2026 Phase\u202f3 Launch\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45331#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest Medicines Secures Exclusive Rights to VIS\u2011101 in Greater China, Potential 2026 Phase\u202f3 Launch\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Everest Medicines Secures Exclusive Rights to VIS\u2011101 in Greater China, Potential 2026 Phase\u202f3 Launch - Insight, China&#039;s Pharmaceutical Industry","description":"Hong Kong\u2011listed Everest Medicines Limited (HKG: 1952) today announced a strategic agreement with Visara, Inc., a subsidiary of NovaBridge Biosciences (formerly I\u2011Mab, Nasdaq:\u202fNBP). Under the deal, Visara irrevocably granted Everest an exclusive license to develop, manufacture, and commercialize the bifunctional biologic VIS\u2011101 in Greater China, Singapore, South\u202fKorea, and selected Southeast Asian markets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45331","og_locale":"en_US","og_type":"article","og_title":"Everest Medicines Secures Exclusive Rights to VIS\u2011101 in Greater China, Potential 2026 Phase\u202f3 Launch","og_description":"Hong Kong\u2011listed Everest Medicines Limited (HKG: 1952) today announced a strategic agreement with Visara, Inc., a subsidiary of NovaBridge Biosciences (formerly I\u2011Mab, Nasdaq:\u202fNBP). Under the deal, Visara irrevocably granted Everest an exclusive license to develop, manufacture, and commercialize the bifunctional biologic VIS\u2011101 in Greater China, Singapore, South\u202fKorea, and selected Southeast Asian markets.","og_url":"https:\/\/flcube.com\/?p=45331","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-30T14:20:43+00:00","article_modified_time":"2025-10-30T14:20:44+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3005-2.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45331#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45331"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Everest Medicines Secures Exclusive Rights to VIS\u2011101 in Greater China, Potential 2026 Phase\u202f3 Launch","datePublished":"2025-10-30T14:20:43+00:00","dateModified":"2025-10-30T14:20:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45331"},"wordCount":377,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45331#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3005-2.webp","keywords":["Everest Medicines","HKG: 1952","NovaBridge Biosciences","Ophthalmology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45331#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45331","url":"https:\/\/flcube.com\/?p=45331","name":"Everest Medicines Secures Exclusive Rights to VIS\u2011101 in Greater China, Potential 2026 Phase\u202f3 Launch - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45331#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45331#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3005-2.webp","datePublished":"2025-10-30T14:20:43+00:00","dateModified":"2025-10-30T14:20:44+00:00","description":"Hong Kong\u2011listed Everest Medicines Limited (HKG: 1952) today announced a strategic agreement with Visara, Inc., a subsidiary of NovaBridge Biosciences (formerly I\u2011Mab, Nasdaq:\u202fNBP). Under the deal, Visara irrevocably granted Everest an exclusive license to develop, manufacture, and commercialize the bifunctional biologic VIS\u2011101 in Greater China, Singapore, South\u202fKorea, and selected Southeast Asian markets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45331#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45331"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45331#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3005-2.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3005-2.webp","width":1080,"height":608,"caption":"Everest Medicines Secures Exclusive Rights to VIS\u2011101 in Greater China, Potential 2026 Phase\u202f3 Launch"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45331#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Everest Medicines Secures Exclusive Rights to VIS\u2011101 in Greater China, Potential 2026 Phase\u202f3 Launch"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3005-2.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45331"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45331\/revisions"}],"predecessor-version":[{"id":45334,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45331\/revisions\/45334"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45333"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}